MDT-AP-0101
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 32.519999999999996
- os_event
- true
- age_years
- 4.48
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.215676476
- umap2_2d
- -0.025602721
- umap1_3d
- 0.356087385
- umap2_3d
- -3.553567129
- umap3_3d
- -0.253587545
- dataset
- Med-Taylor
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R320 | — | — | 0.769 |
| 2 | R288 | — | — | 0.767 |
| 3 | TCGA-62-A46O-01A-11R-A24H-07 | — | cohortA4 | 0.767 |
| 4 | MDT-AP-2631 | Med | Medulloblastoma | 0.759 |
| 5 | MDT-AP-2073 | Med | Medulloblastoma | 0.750 |
| 6 | R411 | — | — | 0.749 |
| 7 | SRR12202430 | — | — | 0.746 |
| 8 | R391 | — | — | 0.745 |
| 9 | 20040104.LumB | — | B | 0.743 |
| 10 | 8ca13509-abad-46b7-92f4-fa741bc52b42 | — | — | 0.742 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |